首页> 外文OA文献 >A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

【2h】

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

机译：组合生物标志物预测对Neoadjuvant Lapatinib和Trastuzumab的病理完全反应而不在患有HER2 +乳腺癌的患者中的化疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J. Veeraraghavan; C. De Angelis; R. Mao; T. Wang; S. Herrera; A.C. Pavlick; A. Contreras; P. Nuciforo; I.A. Mayer; A. Forero; R. Nanda; M.P. Goetz; J.C. Chang; A.C. Wolff; I.E. Krop; S.A.W. Fuqua; A. Prat; S.G. Hilsenbeck; B. Weigelt; J.S. Reis-Filho; C. Gutierrez; C.K. Osborne; M.F. Rimawi; R. Schiff;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial [J] . Llombart-Cussac Antonio, Cortes Javier, Pare Laia, The lancet oncology . 2017,第4期

机译：HER2-富集的亚型作为在早期HER2阳性乳腺癌（PAMELA）的曲妥珠单抗和Lapatinib后病理完全反应的预测因子（帕米拉）：开放标签，单组，多期，第2期试验
2. ER, PgR, Ki67, p27 Kip1 , and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab [J] . Sasagu Kurozumi, Kenichi Inoue, Hiroyuki Takei, BMC Cancer . 2015,第1期

机译：ER，PgR，Ki67，p27 Kip1和组织学等级是HER2阳性乳腺癌患者接受紫杉烷类药物新辅助化疗后再使用氟尿嘧啶，表柔比星和环磷酰胺并伴曲妥珠单抗的病理学完全缓解的指标
3. Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials [J] . Hicks Mellissa, Macrae Erin R., Abdel-Rasoul Mahmoud, The oncologist . 2015,第4期

机译：拉帕替尼和曲妥珠单抗新辅助双重靶向HER2治疗可改善早期HER2阳性乳腺癌患者的病理完全缓解：一项随机前瞻性临床试验的荟萃分析
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data [O] . Tamara Díaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, 2019

机译：不同的病理完全应对率根据PAM50亚型在HER2 +乳腺癌患者中用Neoadjuvant Pertuzumab / rrastuzumab与曲妥珠单抗加标准化疗：现实世界数据分析
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅